Acta obstetricia et gynecologica Scandinavica · 2009
Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumbak Banu, Kahraman Semra
Аннотация
OBJECTIVE: To evaluate the effect of metformin addition during ovarian hyperstimulation on cycle parameters and outcome of in vitro fertilization (IVF) treatment in polycystic ovary syndrome (PCOS) patients with a body mass index (BMI) <28 kg/m(2).
DESIGN: Retrospective review of patients' records.
SETTING: Istanbul Memorial Hospital Assisted Reproductive Treatment Unit.
POPULATION: A total of 339 non-obese PCOS patients undergoing IVF were evaluated according to the supplementation of metformin.
METHODS: Cycle parameters and IVF outcomes of 220 patients given metformin were compared to those of 119 patients treated without metformin.
MAIN OUTCOME MEASURES: Implantation and pregnancy rates.
RESULTS: Metformin co-treatment led to significantly lower peak E2 levels (3,481 pg/ml vs. 4,192 pg/ml; p <0.0001). However, gonadotropin consumption, stimulation duration, numbers of total and mature oocytes retrieved, fertilization rate, and ratio of grade I embryos developed were similar in both groups. In the metformin administered group, significantly higher implantation (25% vs. 18%; p=0.003) and pregnancy rates (58% vs. 45%; p=0.04) were achieved. Abortion and moderate-severe ovarian hyperstimulation syndrome rates were found to be similar in both groups.
CONCLUSIONS: Although metformin use was especially and strongly recommended in obese PCOS cases, its supplementation during IVF in PCOS patients with a BMI <28 kg/m(2) was observed to be beneficial and efficacious.
DESIGN: Retrospective review of patients' records.
SETTING: Istanbul Memorial Hospital Assisted Reproductive Treatment Unit.
POPULATION: A total of 339 non-obese PCOS patients undergoing IVF were evaluated according to the supplementation of metformin.
METHODS: Cycle parameters and IVF outcomes of 220 patients given metformin were compared to those of 119 patients treated without metformin.
MAIN OUTCOME MEASURES: Implantation and pregnancy rates.
RESULTS: Metformin co-treatment led to significantly lower peak E2 levels (3,481 pg/ml vs. 4,192 pg/ml; p <0.0001). However, gonadotropin consumption, stimulation duration, numbers of total and mature oocytes retrieved, fertilization rate, and ratio of grade I embryos developed were similar in both groups. In the metformin administered group, significantly higher implantation (25% vs. 18%; p=0.003) and pregnancy rates (58% vs. 45%; p=0.04) were achieved. Abortion and moderate-severe ovarian hyperstimulation syndrome rates were found to be similar in both groups.
CONCLUSIONS: Although metformin use was especially and strongly recommended in obese PCOS cases, its supplementation during IVF in PCOS patients with a BMI <28 kg/m(2) was observed to be beneficial and efficacious.
Предметные рубрики MeSH
AdultBlood GlucoseBody Mass IndexCase-Control StudiesChorionic GonadotropinDinoprostoneEmbryo ImplantationEmbryo TransferEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGonadotropin-Releasing HormoneHumansHypoglycemic AgentsInfertility, FemaleInsulinInsulin ResistanceLuteinizing HormoneMetforminOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromePregnancyPregnancy RateRetrospective StudiesTreatment OutcomeTurkey